Related Experiment Videos
A cost-effectiveness analysis of stress ulcer prophylaxis
Kelly N Schupp1, Linda M Schrand, Alan H Mutnick
1The University of Iowa Hospitals and Clinics, Iowa City, IA, USA.
The Annals of Pharmacotherapy
|April 24, 2003
Summary
Lansoprazole is the most cost-effective option for stress ulcer prophylaxis (SUP), demonstrating superior efficacy and lower costs compared to cimetidine. This study evaluated three agents for SUP in intensive care units.
Area of Science:
- Critical Care Medicine
- Pharmacoeconomics
- Gastroenterology
Background:
- Stress ulcer prophylaxis (SUP) is crucial for critically ill patients.
- Evaluating the cost-effectiveness of different SUP agents is essential for optimizing healthcare resource allocation.
Purpose of the Study:
- To compare the efficacy, safety, and cost-effectiveness of cimetidine, famotidine, and lansoprazole for SUP.
- To identify the most economical and effective agent for stress ulcer prophylaxis in an intensive care setting.
Main Methods:
- Observational study of adult ICU patients comparing cimetidine, famotidine, and lansoprazole for SUP.
- Data collection on drug administration costs, adverse events, and therapeutic failures.
- Decision analysis and cost-effectiveness analysis to determine the average cost per patient and identify the most cost-effective therapy.
Main Results:
- Lansoprazole showed no therapeutic failures, unlike cimetidine which had five failures.
- Lansoprazole, being an oral agent, incurred lower average costs than cimetidine.
- Lansoprazole was identified as the most cost-effective therapy among the evaluated agents.
Conclusions:
- Lansoprazole is a cost-effective agent for stress ulcer prophylaxis at the institution.
- Intravenous pantoprazole is unlikely to be cost-effective compared to cimetidine due to its higher cost, assuming equal effectiveness.